Featured Research

from universities, journals, and other organizations

Alzheimer's: Therapy for brain disease could target blood

Date:
December 31, 2010
Source:
Rockefeller University
Summary:
The aggregated proteins strewn about the brain are the hallmark of one of the most common neurodegenerative disorders: Alzheimer's disease. But while these irregular, gunky proteins, called amyloid-beta, are believed to contribute to the deterioration of memory and cognitive ability in Alzheimer's patients, no one knows how they lead to these symptoms. New experiments show how amyloid-beta interacts with a clotting agent in the blood, increasing blood clots that are harder than usual to break down and starving neurons of their regular supply of oxygen. The research suggests that the effects of amyloid-beta on the blood vessels feeding the brain could be an important aspect of the havoc they wreak on the brain.

The clot thickens. Researchers found that the main element of Alzheimer's plaques interacts with a blood clotting agent to form irregular clots (right) that are more difficult to break down than typical blood clots (left). They suspect these tenacious clots could reduce blood flow to brain cells, starving them of oxygen and aggravating Alzheimer's pathology.
Credit: Image courtesy of Rockefeller University

The aggregated proteins strewn about the brain are the hallmark of one of the most common neurodegenerative disorders: Alzheimer's disease. But while these irregular, gunky proteins, called amyloid-β, are believed to contribute to the deterioration of memory and cognitive ability in Alzheimer's patients, no one knows how they lead to these symptoms, and the severity of the dementia doesn't directly depend on the amount of amyloid-β plaques found in diseased brains.

New experiments from The Rockefeller University, building on a paper published earlier this year, show how amyloid-β interacts with a clotting agent in the blood, increasing blood clots that are harder than usual to break down and starving neurons of their regular supply of oxygen. The research suggests that the effects of amyloid-β on the blood vessels feeding the brain could be an important aspect of the havoc they wreak on the brain.

"There has been a suggestion that vascular dementia and Alzheimer's disease might be related, and our current work provides a possible connection between the two," says Sidney Strickland, head of the Laboratory of Neurobiology and Genetics at Rockefeller.

Led by Hyung Jin Ahn, a postdoctoral associate in Strickland's lab, researchers used biochemical tests to home in on exactly how a particularly nasty form of amyloid-β, called Aβ42, interacts with the blood clotting agent fibrinogen, causing fibrinogen to grow into unusual clot structures that are hard to degrade. Ahn and colleagues show, by incubating Aβ42 and fibrinogen and studying the effects, exactly what pieces of the molecules interact and what happens when they do. The results indicate that the interaction between Aβ42 and fibrinogen may induce abnormal fibrinogen structures prior to fibrin clot formation and that this oligomeric fibrinogen plays an important role in Alzheimer's disease pathogenesis, Ahn says.

The findings could suggest a drug target for disrupting this interaction, thereby preventing the downstream consequences, which could include decreased blood flow, cognitive dysfunction and inflammation of the neurons.

In June, researchers from the same lab published a report in Neuron demonstrating that amyloid-β leads to the formation of tougher blood clots, and that decreasing the level of fibrinogen could reduce the pathology of Alzheimer's disease. The latest work, published November 22 in Proceedings of the National Academy of Sciences, shows how those tougher blood clots are formed.

Ahn and colleagues are now in the process of identifying small molecules that can inhibit the Aβ42-fibrinogen interaction and hope these inhibitors could become an effective drug therapy for patients with Alzheimer's disease.


Story Source:

The above story is based on materials provided by Rockefeller University. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. J. Ahn, D. Zamolodchikov, M. Cortes-Canteli, E. H. Norris, J. F. Glickman, S. Strickland. Alzheimer's disease peptide -amyloid interacts with fibrinogen and induces its oligomerization. Proceedings of the National Academy of Sciences, 2010; 107 (50): 21812 DOI: 10.1073/pnas.1010373107

Cite This Page:

Rockefeller University. "Alzheimer's: Therapy for brain disease could target blood." ScienceDaily. ScienceDaily, 31 December 2010. <www.sciencedaily.com/releases/2010/12/101230104241.htm>.
Rockefeller University. (2010, December 31). Alzheimer's: Therapy for brain disease could target blood. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/2010/12/101230104241.htm
Rockefeller University. "Alzheimer's: Therapy for brain disease could target blood." ScienceDaily. www.sciencedaily.com/releases/2010/12/101230104241.htm (accessed September 22, 2014).

Share This



More Mind & Brain News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Food Addiction Might Be Caused By PTSD

Food Addiction Might Be Caused By PTSD

Newsy (Sep. 18, 2014) New research shows that women who suffer from PTSD are three times more likely to develop a food addiction. Video provided by Newsy
Powered by NewsLook.com
Corporal Punishment on Decline, Debate Renews

Corporal Punishment on Decline, Debate Renews

AP (Sep. 16, 2014) Corporal punishment in the United States is on the decline, but there is renewed debate over its use after Minnesota Vikings running back Adrian Peterson was charged with child abuse. (Sept. 16) Video provided by AP
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins